Amgen: buys rights on Otezla from Celgene
(CercleFinance.com) - The pharmaceutical group Amgen has announced an agreement with Celgene to buy from it the worldwide rights to Otezla (apremilast), a treatment for psoriasis and psoriatic arthritis, for 13.
4 billion dollars in cash.
This transaction, related to Celgene's upcoming merger with Bristol-Myers Squibb, will accelerate Amgen's short- and long-term revenue growth and have an immediate accretive impact on its adjusted EPS. It is expected to be completed by the end of 2019.
Benefiting from patent exclusivity until at least 2028 in the United States and approved in over 50 other markets worldwide (including the European Union and Japan), Otezla's sales reached 1.6 billion dollars in 2018.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
4 billion dollars in cash.
This transaction, related to Celgene's upcoming merger with Bristol-Myers Squibb, will accelerate Amgen's short- and long-term revenue growth and have an immediate accretive impact on its adjusted EPS. It is expected to be completed by the end of 2019.
Benefiting from patent exclusivity until at least 2028 in the United States and approved in over 50 other markets worldwide (including the European Union and Japan), Otezla's sales reached 1.6 billion dollars in 2018.
Copyright (c) 2019 CercleFinance.com. All rights reserved.